Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Linking epigenetic dysregulation, mitochondrial impairment, and metabolic dysfunction in SBMA motor neurons
Naemeh Pourshafie, Ester Masati, Eric Bunker, Alec R. Nickolls, Parisorn Thepmankorn, Kory Johnson, Xia Feng, Tyler Ekins, Christopher Grunseich, Kenneth H. Fischbeck
Naemeh Pourshafie, Ester Masati, Eric Bunker, Alec R. Nickolls, Parisorn Thepmankorn, Kory Johnson, Xia Feng, Tyler Ekins, Christopher Grunseich, Kenneth H. Fischbeck
View: Text | PDF
Research Article Genetics Neuroscience

Linking epigenetic dysregulation, mitochondrial impairment, and metabolic dysfunction in SBMA motor neurons

  • Text
  • PDF
Abstract

Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disorder caused by a polyglutamine expansion in the androgen receptor (AR). Using gene expression analysis and ChIP sequencing, we mapped transcriptional changes in genetically engineered patient stem cell–derived motor neurons. We found that transcriptional dysregulation in SBMA can occur through AR-mediated histone modification. We detected reduced histone acetylation, along with decreased expression of genes encoding compensatory metabolic proteins and reduced substrate availability for mitochondrial function. Furthermore, we found that pyruvate supplementation corrected this deficiency and improved mitochondrial function and SBMA motor neuron viability. We propose that epigenetic dysregulation of metabolic genes contributes to reduced mitochondrial ATP production. Our results show a molecular link between altered epigenetic regulation and mitochondrial metabolism that contributes to neurodegeneration.

Authors

Naemeh Pourshafie, Ester Masati, Eric Bunker, Alec R. Nickolls, Parisorn Thepmankorn, Kory Johnson, Xia Feng, Tyler Ekins, Christopher Grunseich, Kenneth H. Fischbeck

×

Figure 2

Reduction in H3K27ac binding corresponds to repression in metabolic genes.

Options: View larger image (or click on image) Download as PowerPoint
Reduction in H3K27ac binding corresponds to repression in metabolic gene...
(A) H3K27ac peak distribution near WT AR (top) and mutant AR (bottom) peaks. The H3K27ac signal is shown over a scaled window of ± 10 kb from the AR peak. (B) Heatmap of H3K27ac occupancy signals at ± 10 kb region centered around all Refseq TSS ranked by increasing H3K27ac signal intensity in SBMA over control. The height of the heatmap shows 16,118 H3K27ac binding regions across the genome. (C) Ratiometric heatmap comparing H3K27ac signals. Signals are ranked by increased H3K27ac signal intensity in SBMA/control. Demarcated regions represent H3K27ac occupancy signals with greater than 1.5-fold and 2-fold reduced binding. (D and E) Histograms representing 16,118 H3K27ac signals between SBMA/control and ARKO/control. Boxed regions represent H3K27ac binding regions with greater than 2-fold enrichment (red) and greater than 2-fold reduced binding (blue). iMNs were treated with 10 nM DHT.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts